BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Achillion Pharmaceuticals, Inc. (ACHN) Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for Study of Liver Diseases


11/12/2012 9:21:56 AM

NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ --

Event:

HCV Connection Media Briefing

Date:

Monday, November 12

Time:

7:45 a.m. Eastern Standard Time

Where:

Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199;


Also available by Webcast (link will be provided upon request)

The content of the media briefing will include the following themes and information:

  • An overview of HCV and the current epidemic worldwide
  • A compelling historical and scientific context for understanding the new era of HCV therapies and the emergence of patient-guided therapy
  • A brief review of first and second-generation direct-acting antiviral therapies, including important new developments in drug discovery
  • A detailed look at Achillion Pharmaceutical's portfolio aimed at curing HCV in a complex and diverse patient population

Following the briefing there will be a Question & Answer session with leading experts in HCV including:

  • Fred Poordad, MD, Chief Medical Officer of the Texas Liver Institute and Alamo Medical Research, San Antonio, Texas
  • Andrew Muir, MD, Director, Gastroenterology and Hepatology Research Group, Duke Clinical Research Institute, Durham, North Carolina
  • The session will also be moderated by Lisa Stark of ABC News

Achillion (Nasdaq: ACHN) is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have identified and advanced multiple therapeutic compounds, many with novel mechanisms or attributes. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C (HCV) and resistant bacterial infections. Please visit www.achillion.com for additional information.

SOURCE Achillion Pharmaceuticals, Inc.


Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->